HRP20010773A2 - Thiazolidinedione derivative and its use as antidiabetic - Google Patents
Thiazolidinedione derivative and its use as antidiabetic Download PDFInfo
- Publication number
- HRP20010773A2 HRP20010773A2 HR20010773A HRP20010773A HRP20010773A2 HR P20010773 A2 HRP20010773 A2 HR P20010773A2 HR 20010773 A HR20010773 A HR 20010773A HR P20010773 A HRP20010773 A HR P20010773A HR P20010773 A2 HRP20010773 A2 HR P20010773A2
- Authority
- HR
- Croatia
- Prior art keywords
- polymorph
- diabetes mellitus
- compound
- polymorph according
- accordance
- Prior art date
Links
- 230000003178 anti-diabetic effect Effects 0.000 title description 2
- 239000003472 antidiabetic agent Substances 0.000 title description 2
- 150000001467 thiazolidinediones Chemical class 0.000 title description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 34
- 150000001875 compounds Chemical class 0.000 claims description 34
- 206010012601 diabetes mellitus Diseases 0.000 claims description 20
- 238000000034 method Methods 0.000 claims description 18
- 229940075894 denatured ethanol Drugs 0.000 claims description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 15
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 13
- 238000011282 treatment Methods 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 10
- 238000011321 prophylaxis Methods 0.000 claims description 10
- 239000013543 active substance Substances 0.000 claims description 7
- 239000000126 substance Substances 0.000 claims description 7
- 238000001237 Raman spectrum Methods 0.000 claims description 6
- ZOBPZXTWZATXDG-UHFFFAOYSA-N 1,3-thiazolidine-2,4-dione Chemical compound O=C1CSC(=O)N1 ZOBPZXTWZATXDG-UHFFFAOYSA-N 0.000 claims description 5
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 5
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims description 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 5
- 238000002329 infrared spectrum Methods 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 238000000279 solid-state nuclear magnetic resonance spectrum Methods 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 3
- 150000002689 maleic acids Chemical class 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 231100000252 nontoxic Toxicity 0.000 claims description 3
- 230000003000 nontoxic effect Effects 0.000 claims description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 2
- 239000011976 maleic acid Substances 0.000 claims description 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 2
- 239000002904 solvent Substances 0.000 claims 2
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 21
- 238000002360 preparation method Methods 0.000 description 14
- 239000000243 solution Substances 0.000 description 14
- 239000003981 vehicle Substances 0.000 description 7
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 5
- -1 e.g. Chemical compound 0.000 description 4
- 235000019441 ethanol Nutrition 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 206010022489 Insulin Resistance Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 239000002934 diuretic Substances 0.000 description 3
- 229940030606 diuretics Drugs 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 238000011049 filling Methods 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 238000000862 absorption spectrum Methods 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 208000017169 kidney disease Diseases 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 description 1
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 235000019489 Almond oil Nutrition 0.000 description 1
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000000103 Anorexia Nervosa Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 229940123208 Biguanide Drugs 0.000 description 1
- 208000032841 Bulimia Diseases 0.000 description 1
- 206010006550 Bulimia nervosa Diseases 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 208000002249 Diabetes Complications Diseases 0.000 description 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 208000019454 Feeding and Eating disease Diseases 0.000 description 1
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- 208000002705 Glucose Intolerance Diseases 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 206010060378 Hyperinsulinaemia Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 229940122199 Insulin secretagogue Drugs 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 206010029164 Nephrotic syndrome Diseases 0.000 description 1
- 238000001069 Raman spectroscopy Methods 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229940100389 Sulfonylurea Drugs 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 229960002632 acarbose Drugs 0.000 description 1
- XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- 239000003888 alpha glucosidase inhibitor Substances 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- 229940063655 aluminum stearate Drugs 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 229940127003 anti-diabetic drug Drugs 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940125388 beta agonist Drugs 0.000 description 1
- 150000004283 biguanides Chemical class 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 238000001875 carbon-13 cross-polarisation magic angle spinning nuclear magnetic resonance spectrum Methods 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 150000007942 carboxylates Chemical group 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000007810 chemical reaction solvent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 208000033679 diabetic kidney disease Diseases 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 208000028208 end stage renal disease Diseases 0.000 description 1
- 201000000523 end stage renal failure Diseases 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 208000004104 gestational diabetes Diseases 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 206010061989 glomerulosclerosis Diseases 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000003451 hyperinsulinaemic effect Effects 0.000 description 1
- 201000008980 hyperinsulinism Diseases 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 229960005015 local anesthetics Drugs 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229940095102 methyl benzoate Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 201000009925 nephrosclerosis Diseases 0.000 description 1
- 239000002687 nonaqueous vehicle Substances 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000003182 parenteral nutrition solution Substances 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- 239000008024 pharmaceutical diluent Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000010287 polarization Effects 0.000 description 1
- 201000010065 polycystic ovary syndrome Diseases 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 201000009104 prediabetes syndrome Diseases 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 235000018770 reduced food intake Nutrition 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000009827 uniform distribution Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Description
Ovaj izum odnosi se na novu farmaceutski aktivnu tvar, na postupak dobivanja farmaceutski aktivne tvari i upotrebu farmaceutski aktivne tvari u medicini.
Međunarodna patentna prijava, objavljena kao WO94/05659 opisuje izvjesne derivate tiazolidindiona s hipoglikemijskom i hiperlipidemijskom aktivnošću, uključujući 5[4[2(NmetilN(2piridil)amino)etoksi]benzil]tiazolidin2,4dion, sol maleinske kiseline (nadalje ga se navodi kao "spoj (I)").
Od Međunarodnih patentnih prijava, objavljenih kao WO99/31093, WO99/31094 i WO99/31095 svaka opisuje različite hidrate spoja (I).
U novije vrijeme otkriveno je da spoj (I) postoji u novoj polimorfnoj formi, koja je osobito pogodna za masovnu proizvodnju i rukovanje. Nova forma može se proizvesti djelotvornim, ekonomičnim i ponovljivim postupkom, osobito pogodnim za industrijsku proizvodnju.
Nova polimorfna forma ("polimorf") također posjeduje korisna farmaceutska svojstva, a osobito se navodi da je korisna u liječenju i/ili profilaksi dijabetes melitusa, stanja povezanih s dijabetes melitusom izvjesnih njihovih komplikacija.
Prema tome, ovaj izum se odnosi na polimorfnu formu 5[4[2(NmetilN(2piridil)amino)etoksi]benzil]tiazolidin2,4diona, sol maleinske kiseline, koja je karakterizirana time što:
(i) njen infracrveni spektar ima istaknute vrijednosti na 1360, 1326, 1241, 714 i 669 cm–1; i/ili
(i) njen Ramanov spektar ima istaknute vrijednosti na 1581, 768, 670, 271 i 226 cm–1; i/ili
(i) njen spektar nuklearne magnetske rezonancije čvrstog stanja ima istaknute vrijednosti kod kemijskih pomaka kako je uglavnom navedeno u tablici I; i/ili
(i) njen uzorak difrakcije Xzraka na prahu (X-ray powder diffraction, XRPD) ima istaknute vrijednosti kako je uglavnom navedeno u tablici II.
U jednom povoljnom aspektu polimorf ima infracrveni spektar uglavnom u skladu sa slikom I.
U jednom povoljnom aspektu polimorf ima Ramanov spektar uglavnom u skladu sa slikom II.
U jednom povoljnom aspektu polimorf ima spektar nuklearne magnetske rezonancije čvrstog stanja uglavnom u skladu sa slikom III.
U jednom povoljnom aspektu polimorf ima uzorak difrakcije Xzraka na prahu (XRPD) uglavnom u skladu sa slikom IV.
Ovaj izum obuhvaća polimorf izdvojen u čistoj formi ili u smjesi s drugim materijalima, primjerice poznatim formama spoja I spoja I ili bilo kojim drugim materijalom.
Prema tome, u jednom aspektu polimorf je u izdvojenoj formi.
U daljnjem aspektu polimorf je u čistoj formi.
U još daljnjem aspektu polimorf je u kristalnoj formi.
Ovaj izum također se odnosi na postupak dobivanja polimorfa, karakteriziran time što se gustu otopinu spoja (I) u smjesi etanola i vode, koja sadrži do oko 2,5 %, težinski, po jedinici volumena vode, osobito u smjesi denaturiranog etanola i vode, koja sadrži do oko 2,5 %, težinski, po jedinici volumena vode, grije, po mogućnosti na temperaturi raspona od 3560 °C, kao npr. od 4050 °C, npr. 45 °C, kroz dulji period vremena, primjerice 65 sati, nakon čega se polimorf prikuplja iz denaturiranog etanola. Izborno, reakcijsku smjesu se zasije polimorfom.
U daljnjem postupku iz ovog izuma, spoj (I) se umiješa u denaturirani etanol, grije na povišenoj temperaturi, po mogućnosti na temperaturi raspona od 3560 °C, kao npr. od 4050 °C, npr. 4547 °C, kroz dulji period vremena, primjerice 65 sati, nakon čega se polimorf prikuplja iz denaturiranog etanola. Izborno, reakcijsku smjesu se zasije polimorfom.
U daljnjem postupku otopinu spoja (I) u denaturiranom etanolu sadrži do oko 2,5 %, težinski, po jedinici volumena vode, primjerice od 0,82,5 %, težinski, po jedinici volumena vode, na 55 °C se zasije polimorfom, a zatim ohladi na temperaturu raspona od 2025 °C, kako bi se dobilo polimorf. Polimorf se zatim prikuplja iz denaturiranog etanola.
Otopinu spoja (I) u denaturiranom etanolu se dobije na pogodan način otapanjem spoja (I) u traženoj količini denaturiranog etanola na povišenoj temperaturi, primjerice 65 °C. Dalje se ovaj potonji postupak također djelotvorno provodi pomoću spoja (I) koji sadrži do 25 %, težinski, hidrata opisanog u gore navedenom dokumentu WO99/31093.
Polimorf se na pogodan način prikuplja iz reakcijskog otapala, poput denaturiranog etanola, filtracijom uz naknadno sušenje, po mogućnosti na povišenoj temperaturi, npr. 45 °C.
U daljnjem aspektu, ovaj izum se također odnosi na postupak dobivanja spoja (I) (kojeg se također, pogodnosti radi, navodi kao "izvorni polimorf") iz polimorfa iz ovog izuma, gdje se dotični postupak sastoji prije svega u pripremanju otopine polimorfa u smjesi (100:1 volumno) apsolutnog etanola i metanola na povišenoj temperaturi, po mogućnosti u rasponu od 6075 °C, npr. na 68 °C, a zatim se otopinu pusti neka se ohladi do temperature okoliša, npr. 2025 °C, omogućivši tako kristalizaciju izvornog polimorfa.
U poželjnoj varijanti navedenog postupka dobivanja izvornog polimorfa, otopinu polimorfa u smjesi apsolutni etanol/metanol se filtrira, obično kad se polimorf posve otopi, a dobivenu otopinu je ponovno zagrije na povišenu temperaturu, primjerice na 65 °C, zatim se navedenu otopinu pusti neka se ohladi na temperaturu okoliša, primjerice na 2025 °C.
U gore navedenom postupku dobivanja izvornog polimorfa otopinu se može zasijati izvornim polimorfom, no to nije obavezno.
Spoj (I) se dobiva poznatim postupcima, poput onih opisanih u dokumentu WO94/05659. Opisi iz dokumenta WO94/05659 ovdje su uključeni referencom.
Kako bi se izbjeglo dvojbu, izraz "spoj (I)", kao što se koristi u ovom dokumentu, odnosi se na 5[4[2(NmetilN(2piridil)amino)etoksi]benzil]tiazolidin2,4dion, sol maleinske kiseline, kao što je opisan i okarakteriziran u Međunarodnoj patentnoj prijavi, objavljenoj kao WO94/05659.
Kada se upotrebljava ovdje, izraz "denaturirani etanol" odnosi se na etanol koji sadrži male količine metanola, obično do 5 %, volumno, npr. od 0,95 %, volumno, metanola, npr. etanol koji sadrži 4 %, volumno, metanola.
Kada se upotrebljava ovdje, izraz "profilaksa stanja povezanih s dijabetes melitusom" uključuje liječenje stanja poput otpornosti na inzulin, smanjene tolerancije na glukozu, hiperinzulinemije i dijabetesa trudnica.
Dijabetes melitus po mogućnosti znači dijabetes melitus tipa II.
Stanja povezana s dijabetesom uključuju hiperglikemiju i otpornost na inzulin i pretilost. Daljnja stanja povezana s dijabetesom uključuju hipertenziju, kardiovaskularnu bolest, osobito aterosklerozu, izvjesne poremećaje hranjenja, uključujući reguliranje teka i unošenje hrane u subjekte koji pate od poremećaja povezanih sa smanjenim unosom hrane, poput anoreksije nervoze, i poremećaja povezanih s pretjeranim unosom hrane, poput pretilosti i anoreksije bulimije. Daljnji poremećaji povezani s dijabetesom uključuju sindrom policističnih jajnika i steroidima uzrokovanu otpornost na inzulin.
Komplikacije ovdje obuhvaćenih stanja povezanih dijabetes melitusom uključuju bubrežnu bolest, osobito bubrežnu bolest povezanu s razvojem dijabetesa tipa II, uključujući dijabetičku nefropatiju, glomerulonefritis, sklerozu glomerulosklerozu, nefrotski sindrom, hipertenzivnu nefrosklerozu i krajnji stadij bubrežne bolesti.
Kao što je navedeno gore, spoj iz ovog izuma ima korisna terapijska svojstva: ovaj izum odnosi se na upotrebu polimorfa kao terapijski aktivna tvar.
Specifičnije, ovaj izum odnosi se na upotrebu polimorfa u liječenju i profilaksi dijabetes melitusa i njegovih izvjesnih komplikacija.
Polimorf se može primijeniti sam za sebe ili, po mogućnosti, kao farmaceutski pripravak koji također sadrži farmaceutski prihvatljivu podlogu. Pripravak polimorfa i njegova doziranja su općenito opisani kao za spoj (I) u Međunarodnim patentnim prijavama, objavljenim kao WO94/05659 i WO98/55122.
Prema tome, ovaj izum se također odnosi na farmaceutski pripravak koji sadrži polimorf i farmaceutski prihvatljivu podlogu.
Polimorf se normalno primjenjuje u obliku jedinice doziranja.
Aktivni spoj može se primijeniti bilo kojim pogodnim načinom, no obično je to na oralni ili parenteralni način. Prilikom takve upotrebe, spoj će se normalno upotrijebiti u obliku farmaceutskog pripravka s dodatkom farmaceutske podloge, razrjeđivača i/ili ekscipijensa, iako će prirodno stvarni oblik pripravka ovisiti o načinu primjene.
Pripravke se pripravlja miješanjem i pogodno su prilagođeni oralnoj, parenteralnoj ili topikalnoj primjeni, te kao takvi mogu biti u obliku tableta, kapsula, oralnih tekućih pripravaka, praškova, granula, pilula, pastila, praškova za rekonstituciju, injektibilnih i infuzibilnih otopina ili suspenzija, supozitorija i transdermalnih terapijskih sustava. Preferira se oralno primjenjive pripravke, kao osobito oblikovani oralni pripravci, jer su tako pogodniji za opću primjenu.
Tablete i kapsule namijenjene oralnoj primjeni obično su u obliku jedinice doziranja i sadrže konvencionalne ekscipijense, poput veziva, punila, razrjeđivača, tabletirajućih tvari, maziva, dezintegransa, bojila, aroma i močila. Tablete mogu biti prevučene putem postupaka dobro poznatih u ovom području tehnike.
Pogodna punila namijenjena toj upotrebi uključuju celulozu, manitol, laktozu i druge slične tvari. Pogodni dezintegransi uključuju škrob, polivinilpirolidon i derivate škroba, poput natrijevog škrobnog glikolata. Pogodna maziva uključuju, primjerice, magnezijstearat. Pogodna farmaceutski prihvatljiva močila uključuju natrijlaurilsulfat.
Krute oralne pripravke može se pripraviti konvencionalnim postupcima miješanja, punjenja, tabletiranja i slično. Ponovljene postupke miješanja može se upotrijebiti u distribuciji aktivne tvari u pripravcima koji sadrže velike količine punila. Takvi postupci su, naravno, konvencionalni u ovom području tehnike.
Tekući oralni pripravci mogu biti u obliku, primjerice, vodenih ili uljnih suspenzija, otopina, emulzija, sirupa ili ljekovitih napitaka, ili mogu biti u obliku suhog proizvoda namijenjenog rekonstituciji s vodom ili drugim pogodnim vehikulumom prije upotrebe. Takvi tekući pripravci mogu sadržavati konvencionalne aditive, poput suspendirajućih tvari, primjerice sorbitola, sirupa, metilceluloze, želatine, hidroksietilceluloze, karboksimetilceluloze, aluminijstearatnog gela ili hidrogeniranih jestivih masti, emulgatora, primjerice lecitina, sorbitanmonooleata ili arapske gume; nevodenih vehikuluma (što može uključivati jestiva ulja), poput bademovog ulja, frakcioniranog kokosovog ulja, uljnih estera, poput estera glicerina, propilenglikola ili etilalkohola; konzervansa, primjerice metil ili propilphidroksi benzoata ili sorbinske kiseline, te, ako se želi, konvencionalnih aroma ili bojila.
Prilikom parenteralne primjene, tekuće oblike jedinica doziranja se pripravlja tako da sadrže spoj iz ovog izuma i sterilni vehikulum. Spoj, ovisno o vehikulumu i koncentraciji, može biti suspendiran ili otopljen. Parenteralne otopine se normalno pripravlja otapanjem aktivnog spoja u vehikulumu i steriliziranjem filtriranjem prije punjenja u odgovarajuće fijale ili ampule prije hermetičnog zatvaranja. Po mogućnost, adjuvansi, poput lokalnog anestetika, konzervansa i puferirajućih tvari, su također otopljeni u vehikulumu. Radi poboljšanja stabilnosti, pripravak se može zamrznuti nakon punjenja u fijalu, a vodu se ukloni pod vakuumom.
Parenteralne suspenzije se pripravlja na uglavnom isti način, s tim što se aktivni spoj suspendira u vehikulumu umjesto da ga se otopi, te sterilizira izlaganjem etilenoksidu prije suspendiranja u sterilnom vehikulumu. Po mogućnosti, surfaktant ili močilo je uključeno u pripravak, kako bi se pospješilo jednoličnu raspodjelu aktivnog spoja.
Osim toga, takvi pripravci mogu sadržavati još aktivnih tvari, poput antihipertenziva i diuretika.
Osim toga, polimorf se može upotrijebiti u kombinaciji s drugim antidijabeticima, poput sekretagoga inzulina, poput sulfonilureja, bigvanida, poput metmorfina, inhibitora alfaglukozidaze, poput akarboze, betaagonista, te inzulina, kao što je opisano u dokumentima WO98/57649, WO98/57634, WO98/57635 ili WO98/57636. Količine i postupci primjene drugih antidijabetika opisani su u gore navedenim dokumentima. Pripravak polimorfa i njegova doziranja u navedenim kombinacijama općenito su opisani za spoj (I) u gore navedenim dokumentima. Prema uobičajenoj praksi, uz pripravke će općenito biti pridodate pisane ili tiskane upute za upotrebu, koje se tiču upotrebe u medicinskom liječenju.
Kao što se ovdje upotrebljava, izraz "farmaceutski prihvatljiv" obuhvaća spojeve, pripravke i sastojke namijenjeni upotrebi na ljudima i u veterini: primjerice, izraz "farmaceutski prihvatljiva sol" obuhvaća veterinarski prihvatljivu sol.
Ovaj izum se još odnosi na postupak liječenja i/ili profilakse dijabetes melitusa, stanja povezanih dijabetes melitusom i izvjesnih njihovih komplikacija kod čovjeka ili sisavca koji nije čovjek, što obuhvaća primjenu djelotvorne, neotrovne količine polimorfa na čovjeku ili sisavcu koji nije čovjek, kojima je to potrebno.
Po mogućnost, aktivni sastojak se može primijeniti u obliku farmaceutskog pripravka koji je prethodno definiran u ovom dokumentu, a to predstavlja jedan aspekt ovog izuma.
Prilikom liječenja i/ili profilakse dijabetes melitusa, stanja povezanih s dijabetes melitusom i izvjesnih njihovih komplikacija, polimorf se može unijeti u dozama poput gore opisanih.
Slični režimi doziranja pogodni su u liječenju i/ili profilaksi sisavaca koji nisu ljudi.
U daljnjim aspektima, ovaj izum se odnosi na upotrebu polimorfa u proizvodnji lijeka namijenjenog liječenju i/ili profilaksi dijabetes melitusa, stanja povezanih s dijabetes melitusom i izvjesnih njihovih komplikacija.
U gore navedenom liječenju nema naznake nepovoljnog otrovnog djelovanja.
Slijedeći primjeri ilustriraju ovaj izum, no ne ograničuju ga ni na koji način.
PRIMJERI
Primjer 1
Gustu otopina spoja (I) (3,0 g, pripravljenog u skladu s dokumentom WO94/05659, u denaturiranom etanolu (30,5 ml, količina vode: 2,5 % težinski, po jedinici volumena)) grije se na 45 °C 65 sati. Produkt se filtrira na 45 °C i osuši na 50 °C pod vakuumom, kako bi se dobilo polimorf (1,55 g).
Primjer 2
U smjesu apsolutnog etanola (30 ml, voda <0,1 % težinski, po jedinici volumena) i metanola (1,2 ml) doda se spoj (I) (2,00 g). Dobivenu suspenziju se zagrije na 4547 °C i drži na toj temperaturi 65 sati. Krutinu se izdvoji na 45 °C i osuši na 50 °C pod vakuumom, kako bi se dobilo 0,83 g polimorfa (41 %).
Primjer 3
Spoj (I) (6,0 g, sadrži približno 25 %, težinski, hidrata opisanog u dokumentu WO99/31093) grije se na 60 °C u denaturiranom etanolu (60 ml, količina vode: 0,8 % težinski, po jedinici volumena) dok se posve ne otopi. Dobivenu otopinu ohladi se na 55 °C, zasije naslovnim spojem (0,06 g), a zatim ohladi na 2025 °C. Produkt se filtrira, ispere denaturiranim etanolom (10 ml) i osuši na 50 °C pod vakuumom, kako bi se dobilo polimorf (4,8 g, 80 %).
Primjer 4
Prevođenje polimorfa u spoj (I) (izvorni polimorf):
Polimorf (4,0 g) se grije na 68 °C u smjesi apsolutnog etanola (40 ml) i metanola (0,4 ml) dok se posve ne otopi. Dobivenu otopinu se filtrira, ponovno zagrije na 65 °C, zatim ohladi do 2025 °C. Produkt se filtrira, ispere apsolutnim etanolom (8 ml) i osuši na 50 °C pod vakuumom, kako bi se dobilo spoj (I), kao što je opisano u dokumentu WO94/05659 (3,32 g, 83 %).
KARAKTERISTIČNI PODACI
Ovo su karakteristični podaci dobiveni za polimorf:
A Količina vode
Određena je na 0,08 %, težinski, pomoću Karl Fischerovim uređajem.
B Infracrveni apsorpcijski spektar
Infracrveni apsorpcijski spektar disperzije polimorfa u mineralnom ulju dobiven je Nicolet 710 FTIR spektrometrom, u rezoluciji od 2 cm–1. Podaci su digitalizirani u intervalima od po 1 cm–1. Dobiveni spektar prikazan je na slici I. Položaji istaknutih vrijednosti su slijedeći: 2720, 1750, 1703, 1640, 1618, 1610, 1573, 1541, 1529, 1513, 1412, 1400, 1360, 1326, 1309, 1300, 1265, 1241, 1213, 1183, 1162, 1112, 1096, 1080, 1068, 1033, 1014, 989, 972, 933, 902, 866, 843, 832, 812, 774, 741, 734, 729, 669, 660, 636, 613, 605, 577, 558, 540, 527, 515, 508 i 473 cm–1.
C Ramanov spektar
Ramanov spektar polimorfa snimljen je kroz staklenu fijalu Perkin Elmer 2000R spektrometrom, u rezoluciji od 4 cm–1 i prikazan je na slici II (xos pokazuje intenzitet, a yos pokazuje Ramanov pomak u cm–1, 18002000 cm–1). Pobuda je vršena Nd:YAG laserom (1064 nm), izlazne snage 400 mW. Položaji istaknutih vrijednosti su slijedeći: 1749, 1706, 1683, 1611, 1581, 1546, 1511, 1468, 1445, 1435, 1388, 1361, 1327, 1301, 1269, 1250, 1229, 1210, 1179, 1149, 1103, 1056, 1036, 1024, 1005, 989, 920, 843, 827, 800, 782, 768, 744, 722, 670, 637, 605, 560, 541, 512, 473, 429, 408, 397, 347, 322, 298, 271 i 226 cm–1.
D NMR spektar
90,56 MHz 13C CPMAS NMR spektar polimorfa prikazan je na slici III. Kemijski pomaci su dani u tablici I. Podaci su snimljeni na sobnoj temperaturi, uz 10 kHz spinsku frekvenciju, na Bruker AMX360 spektrometru, uz ukriženu polarizaciju od 1,6 ms, te uz vrijeme ponavljanja 15 s. Kemijski pomaci se navode izvana u odnosu na karboksilatni signal u uzorku iz glicinskog testa, na 176,4 ppm u odnosu na tetrametilsilan i smatra ih se točnim u okviru ± 0,5 ppm. Istaknute vrijednosti nisu označene.
Tablica I.
13C kemijski pomaci polimorfa
[image]
E Difrakcija Xzraka na prahu (XRPD)
Uzorak XRPD polimorfa prikazan je niže, na slici IV, a sažeti prikaz XRPD kuteva i izračunatih razmaka rešetke karakterističnih za polimorf dani su tablici II.
U dobivanju uzorka na prahu upotrebljen je PW1710 difraktometar Xzraka na prahu (izvor CU Xzraka), uz slijedeće uvjete dobivanja:
[image]
Tablica II
Kutevi difrakcije Xzraka na prahu i izračunati razmaci rešetke karakteristični za polimorf
[image] [image]
Claims (14)
1. Polimorfna forma 5[4[2(NmetilN(2piridil)amino)etoksi]benzil]tiazolidin2,4diona, soli maleinske kiseline ("Polimorf"), naznačena time što:
(i) njen infracrveni spektar ima istaknute vrijednosti na 1360, 1326, 1241, 714 i 669 cm–1; i/ili
(i) njen Ramanov spektar ima istaknute vrijednosti na 1581, 768, 670, 271 i 226 cm–1; i/ili
(i) njen spektar nuklearne magnetske rezonancije čvrstog stanja ima istaknute vrijednosti kod kemijskih pomaka kako je uglavnom navedeno u tablici I; i/ili
(i) njen uzorak difrakcije Xzraka na prahu (X-ray powder diffraction, XRPD) ima istaknute vrijednosti kako je uglavnom navedeno u tablici II.
2. Polimorf prema zahtjevu 1, naznačen time što je njegov infracrveni spektar uglavnom u skladu sa slikom I.
3. Polimorf prema zahtjevu 1 ili zahtjevu 2, naznačen time što je njegov Ramanov spektar uglavnom u skladu sa slikom II.
4. Polimorf prema bilo kojem zahtjevu od 1-3, naznačen time što je njegov spektar nuklearne magnetske rezonancije čvrstog stanja uglavnom u skladu sa slikom III.
5. Polimorf prema bilo kojem zahtjevu od 1-4, naznačen time što je njegov uzorak difrakcije Xzraka na prahu (XRPD) uglavnom u skladu sa slikom IV.
6. Polimorf prema bilo kojem zahtjevu od 1-5, naznačen time što je u izdvojenoj formi.
7. Polimorf prema bilo kojem zahtjevu od 1-6, naznačen time što je u čistoj formi.
8. Polimorf prema bilo kojem zahtjevu od 1-7, naznačen time što je u kristalnoj formi.
9. Postupak dobivanja polimorfa prema zahtjevu 1, naznačen time što:
(a) gustu otopinu 5[4[2(NmetilN(2piridil)amino)etoksi]benzil]tiazolidin2,4diona, soli maleinske kiseline, (dalje se navodi kao "spoj (I)" ili "izvorni polimorf") u smjesi etanola i vode, koja sadrži do oko 2,5 %, težinski, po jedinici volumena vode, se grije kroz dulji period vremena; nakon toga se polimorf prikuplja iz denaturiranog etanola; ili
(a) spoj (I) se umiješa u denaturirani etanol, grije na povišenoj temperaturi kroz dulji period vremena, nakon čega se polimorf prikuplja iz otapala; ili
(a) spoj (I) u denaturiranom etanolu sadrži do oko 2,5 %, težinski, po jedinici volumena vode, na 55 °C se zasije polimorfom, a zatim ohladi na temperaturu raspona od 2025 °C, kako bi se dobilo polimorf;
polimorf se zatim prikuplja iz otapala.
10. Farmaceutski pripravak naznačen time što sadrži djelotvornu, neotrovnu količinu polimorfa prema zahtjevu 1 i odgovarajuću farmaceutski prihvatljivu podlogu.
11. Polimorf prema zahtjevu 1, naznačen time što je namijenjen upotrebi kao terapijski aktivna tvar.
12. Polimorf prema zahtjevu 1, naznačen time što je namijenjen liječenju i/ili profilaksi dijabetes melitusa, stanja povezanih s dijabetes melitusom i izvjesnih njihovih komplikacija.
13. Upotreba polimorfa prema zahtjevu 1, naznačen time što je namijenjena proizvodnji lijeka namijenjenog liječenju i/ili profilaksi dijabetes melitusa, stanja povezanih s dijabetes melitusom i izvjesnih njihovih komplikacija.
14. Postupak liječenja i/ili profilakse dijabetes melitusa, stanja povezanih s dijabetes melitusom i izvjesnih njihovih komplikacija kod čovjeka ili sisavca koji nije čovjek, naznačen time što se sastoji u primjeni djelotvorne, neotrovne količine polimorfa na čovjeku ili sisavcu koji nije čovjek, kojima je to potrebno.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9909472.4A GB9909472D0 (en) | 1999-04-23 | 1999-04-23 | Novel compounds |
| GBGB9912197.2A GB9912197D0 (en) | 1999-05-25 | 1999-05-25 | Novel pharmaceutical |
| PCT/GB2000/001514 WO2000064892A2 (en) | 1999-04-23 | 2000-04-19 | Thiazolidinedione derivative and its use as antidiabetic |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HRP20010773A2 true HRP20010773A2 (en) | 2002-10-31 |
| HRP20010773B1 HRP20010773B1 (en) | 2005-06-30 |
Family
ID=26315460
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20010773A HRP20010773B1 (en) | 1999-04-23 | 2001-10-22 | Thiazolidinedione derivative and its use as antidiabetic |
Country Status (40)
| Country | Link |
|---|---|
| US (2) | US6815457B1 (hr) |
| EP (3) | EP1284268B1 (hr) |
| JP (1) | JP2002543075A (hr) |
| KR (1) | KR100744359B1 (hr) |
| CN (1) | CN1208335C (hr) |
| AP (1) | AP1495A (hr) |
| AR (2) | AR023568A1 (hr) |
| AT (2) | ATE382046T1 (hr) |
| AU (1) | AU765498B2 (hr) |
| BG (1) | BG65427B1 (hr) |
| BR (1) | BR0009934A (hr) |
| CA (1) | CA2370258A1 (hr) |
| CO (1) | CO5170424A1 (hr) |
| CY (1) | CY1107238T1 (hr) |
| CZ (1) | CZ20013799A3 (hr) |
| DE (2) | DE60004658T2 (hr) |
| DK (2) | DK1173434T3 (hr) |
| DZ (1) | DZ3155A1 (hr) |
| EA (1) | EA004534B1 (hr) |
| ES (2) | ES2204557T3 (hr) |
| HK (2) | HK1045154B (hr) |
| HR (1) | HRP20010773B1 (hr) |
| HU (1) | HUP0200929A3 (hr) |
| IL (1) | IL146110A0 (hr) |
| MA (1) | MA26785A1 (hr) |
| MX (1) | MXPA01010820A (hr) |
| MY (1) | MY128007A (hr) |
| NO (1) | NO320589B1 (hr) |
| NZ (1) | NZ515163A (hr) |
| OA (1) | OA11871A (hr) |
| PE (1) | PE20010040A1 (hr) |
| PL (1) | PL351686A1 (hr) |
| PT (2) | PT1173434E (hr) |
| RS (1) | RS50114B (hr) |
| SK (1) | SK286423B6 (hr) |
| TR (1) | TR200103061T2 (hr) |
| TW (1) | TW591027B (hr) |
| UA (1) | UA67843C2 (hr) |
| UY (1) | UY26120A1 (hr) |
| WO (1) | WO2000064892A2 (hr) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9726568D0 (en) | 1997-12-16 | 1998-02-11 | Smithkline Beecham Plc | Novel pharmaceutical |
| US20020137940A1 (en) * | 1997-12-16 | 2002-09-26 | Smithkline Beecham P.L.C. | 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2, 4-dione, maleic acid salt, hydrate as pharmaceutical |
| US6664278B2 (en) | 1997-12-16 | 2003-12-16 | Smithkline Beecham P.L.C. | Hydrate of 5-[4-[2-(N-methyl-N-(2-pyridil)amino)ethoxy]benzyl]thiazolidine-2,4-dione maleic acid salt |
| ATE246191T1 (de) | 1999-04-23 | 2003-08-15 | Smithkline Beecham Plc | Polymorph von 5-(4-(2-(n-methyl-n-(2- pyrdyl)amino)äthoxy)benzyl)thiazolidin-2,4-dion maleinsäuresalz |
| US20040248945A1 (en) | 1999-04-23 | 2004-12-09 | Smithkline Beecham P.L.C. | Thiazolidinedione derivative and its use as antidiabetic |
| AR023568A1 (es) | 1999-04-23 | 2002-09-04 | Smithkline Beecham Plc | Un procedimiento para preparar una forma polimorfica de sal de acido maleico derivado de tiazolidina-2,4-diona |
| GB0006133D0 (en) | 2000-03-14 | 2000-05-03 | Smithkline Beecham Plc | Novel pharmaceutical |
| WO2002026737A1 (en) * | 2000-09-26 | 2002-04-04 | Dr. Reddy's Research Foundation | Novel polymorphic forms of 5-[4-[2-[n-methyl-n-(2-pyridyl)amino]ethoxy]benzyl] thiazolidine-2,4-dione maleate and process for their preparation |
| US7241895B2 (en) * | 2000-09-26 | 2007-07-10 | Dr. Reddy's Laboratories Limited | Polymorphic forms of 5-[4-[2-[n-methyl-n-(2-pyridyl)amino[ethoxy]benzyl] thiazolidine-2,4-dione maleate and process for their preparation |
| WO2003050116A1 (en) * | 2001-12-13 | 2003-06-19 | Smithkline Beecham Plc | A 5(-4-(2-(n-methyl-n-(2-pyridil)amino)ethoxy)benzyl)thiazolidine-2,4-dione (i) 10-camphorsulphonic acid salt and use against diabetes mellitus |
| AU2002352479A1 (en) * | 2001-12-20 | 2003-07-09 | Smithkline Beecham Plc | 5- (4- (2- (n-methyl-n- (2-pyridyl) amino) ethoxy) benzyl) thiazolidine-2, 4-dione malic acid salt and use against diabetes mellitus |
| GB0130511D0 (en) * | 2001-12-20 | 2002-02-06 | Smithkline Beecham Plc | Novel pharmaceutical |
| GB0307259D0 (en) * | 2003-03-28 | 2003-05-07 | Glaxo Group Ltd | Process |
| EP1468997A3 (en) * | 2003-04-18 | 2004-11-03 | CHEMI S.p.A. | Polymorphous forms of rosiglitazone maleate |
| GB2405403A (en) * | 2003-08-29 | 2005-03-02 | Cipla Ltd | Rosiglitazone maleate of particular polymorphic forms and methods of preparing rosiglitazone free base |
| EP1709038A2 (en) * | 2004-01-28 | 2006-10-11 | Usv Limited | A process for the preparation of 5- 4- 2- n-methyl -n-(2-pyridyl) amino ethoxy phenyl methyl thiaz olidine-2, 4-dione maleate |
| ITMI20041537A1 (it) * | 2004-07-28 | 2004-10-28 | Chemi Spa | Nuova forma polimorfa del rosiglitazone maleato |
| CZ298424B6 (cs) * | 2005-05-24 | 2007-09-26 | Zentiva, A. S. | Zpusob krystalizace rosiglitazonu a jeho derivátuze smesných rozpouštedel |
| US7435741B2 (en) | 2006-05-09 | 2008-10-14 | Teva Pharmaceutical Industries, Ltd. | 2-N{5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2,4-thiazolidinedione} butanedioic acid, methods of preparation and compositions with rosiglitazone maleate |
| US20090076093A1 (en) * | 2007-09-14 | 2009-03-19 | Protia, Llc | Deuterium-enriched rosiglitazone |
| EP2184055A1 (en) | 2008-11-07 | 2010-05-12 | LEK Pharmaceuticals d.d. | Process for preparing solid dosage forms of rosiglitazone maleate |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6288095B1 (en) | 1987-09-04 | 2001-09-11 | Beecham Group P.L.C. | Compounds |
| SG59988A1 (en) | 1987-09-04 | 1999-02-22 | Beecham Group Plc | Substituted thiazolidinedione derivatives |
| GB9124513D0 (en) | 1991-11-19 | 1992-01-08 | Smithkline Beecham Plc | Novel process |
| GB9218830D0 (en) | 1992-09-05 | 1992-10-21 | Smithkline Beecham Plc | Novel compounds |
| US5741803A (en) | 1992-09-05 | 1998-04-21 | Smithkline Beecham Plc | Substituted thiazolidinedionle derivatives |
| US5478852C1 (en) * | 1993-09-15 | 2001-03-13 | Sankyo Co | Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of impaired glucose tolerance in order to prevent or delay the onset of noninsulin-dependent diabetes mellitus |
| WO1995021608A1 (en) | 1994-02-10 | 1995-08-17 | Smithkline Beecham Plc | Use of insulin sensitisers for treating renal diseases |
| US20010044458A1 (en) * | 1994-02-10 | 2001-11-22 | Smithkline Beechamp P.L.C. | Use of insulin sensitisers for treating renal diseases |
| DE4404198A1 (de) | 1994-02-10 | 1995-08-17 | Henkel Kgaa | 2-Fluor-6-nitroaniline |
| TW438587B (en) * | 1995-06-20 | 2001-06-07 | Takeda Chemical Industries Ltd | A pharmaceutical composition for prophylaxis and treatment of diabetes |
| US6153632A (en) * | 1997-02-24 | 2000-11-28 | Rieveley; Robert B. | Method and composition for the treatment of diabetes |
| GB9711683D0 (en) | 1997-06-05 | 1997-08-06 | Smithkline Beecham Plc | Composition |
| US20010049380A1 (en) * | 1997-06-18 | 2001-12-06 | Smith Stephen Alistair | Treatment of diabetes with thiazolidinedione and sulphonylurea |
| US20020004515A1 (en) * | 1997-06-18 | 2002-01-10 | Smith Stephen Alistair | Treatment of diabetes with thiazolidinedione and metformin |
| IL133137A (en) | 1997-06-18 | 2004-02-08 | Smithkline Beecham Plc | Pharmaceutical preparations containing 5 - [4 - (-2N) methyl - N - (2 - pyridyl) amino) ethoxy] benzyl] thiazolidine - 2, 4 deion and sulfonyl aura |
| SI0996444T1 (sl) | 1997-06-18 | 2007-08-31 | Smithkline Beecham Plc | Zdravljenje diabetesa s tiazolidindionom in metforminom |
| US20020028768A1 (en) * | 1997-06-18 | 2002-03-07 | Smithkline Beecham P.L.C. | Treatment of diabetes with rosiglitazone and insulin |
| GB9712866D0 (en) | 1997-06-18 | 1997-08-20 | Smithkline Beecham Plc | Novel method of treatment |
| TR199903072T2 (xx) | 1997-06-18 | 2000-07-21 | Smithkline Beecham Plc | Diabetin tiazolidinedion ve alfa-glukosidaz ile tedavisi. |
| US20020016287A1 (en) * | 1997-07-18 | 2002-02-07 | Smithkline Beecham P.L.C. | Treatment of diabetes with thiazolidinedione, insulin secretagogue and diguanide |
| US20020045649A1 (en) * | 1997-07-18 | 2002-04-18 | Smithkline Beecham P.L.C. | Treatment of diabetes with thiazolidinedione and sulphonylurea |
| GB9726563D0 (en) | 1997-12-16 | 1998-02-11 | Smithkline Beecham Plc | Novel pharmaceutical |
| GB9726568D0 (en) * | 1997-12-16 | 1998-02-11 | Smithkline Beecham Plc | Novel pharmaceutical |
| GB9726566D0 (en) * | 1997-12-16 | 1998-02-11 | Smithkline Beecham Plc | Novel pharmaceutical |
| US20020137940A1 (en) | 1997-12-16 | 2002-09-26 | Smithkline Beecham P.L.C. | 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2, 4-dione, maleic acid salt, hydrate as pharmaceutical |
| ATE246191T1 (de) | 1999-04-23 | 2003-08-15 | Smithkline Beecham Plc | Polymorph von 5-(4-(2-(n-methyl-n-(2- pyrdyl)amino)äthoxy)benzyl)thiazolidin-2,4-dion maleinsäuresalz |
| UA67845C2 (uk) | 1999-04-23 | 2004-07-15 | Smithkline Beecham Plc | Поліморф 5-[4-[2- (n-метил-n-(2-піридил)аміно)етокси]бензил]тіазолідин-2,4-діону солі малеїнової кислоти |
| AR023568A1 (es) | 1999-04-23 | 2002-09-04 | Smithkline Beecham Plc | Un procedimiento para preparar una forma polimorfica de sal de acido maleico derivado de tiazolidina-2,4-diona |
| WO2002026737A1 (en) | 2000-09-26 | 2002-04-04 | Dr. Reddy's Research Foundation | Novel polymorphic forms of 5-[4-[2-[n-methyl-n-(2-pyridyl)amino]ethoxy]benzyl] thiazolidine-2,4-dione maleate and process for their preparation |
-
2000
- 2000-04-19 AR ARP000101870A patent/AR023568A1/es unknown
- 2000-04-19 UA UA2001117938A patent/UA67843C2/uk unknown
- 2000-04-19 EP EP02080320A patent/EP1284268B1/en not_active Expired - Lifetime
- 2000-04-19 DZ DZ003155A patent/DZ3155A1/xx active
- 2000-04-19 PT PT00920889T patent/PT1173434E/pt unknown
- 2000-04-19 EP EP07150378A patent/EP1903043A1/en not_active Withdrawn
- 2000-04-19 OA OA1200100275A patent/OA11871A/en unknown
- 2000-04-19 RS YUP-752/01A patent/RS50114B/sr unknown
- 2000-04-19 MX MXPA01010820A patent/MXPA01010820A/es unknown
- 2000-04-19 SK SK1491-2001A patent/SK286423B6/sk not_active IP Right Cessation
- 2000-04-19 CZ CZ20013799A patent/CZ20013799A3/cs unknown
- 2000-04-19 DE DE60004658T patent/DE60004658T2/de not_active Expired - Fee Related
- 2000-04-19 WO PCT/GB2000/001514 patent/WO2000064892A2/en not_active Application Discontinuation
- 2000-04-19 BR BR0009934-1A patent/BR0009934A/pt not_active Application Discontinuation
- 2000-04-19 ES ES00920889T patent/ES2204557T3/es not_active Expired - Lifetime
- 2000-04-19 AT AT02080320T patent/ATE382046T1/de not_active IP Right Cessation
- 2000-04-19 EA EA200101119A patent/EA004534B1/ru not_active IP Right Cessation
- 2000-04-19 NZ NZ515163A patent/NZ515163A/xx unknown
- 2000-04-19 CA CA002370258A patent/CA2370258A1/en not_active Abandoned
- 2000-04-19 CO CO00028932A patent/CO5170424A1/es not_active Application Discontinuation
- 2000-04-19 JP JP2000614244A patent/JP2002543075A/ja active Pending
- 2000-04-19 DK DK00920889T patent/DK1173434T3/da active
- 2000-04-19 AT AT00920889T patent/ATE247653T1/de not_active IP Right Cessation
- 2000-04-19 TR TR2001/03061T patent/TR200103061T2/xx unknown
- 2000-04-19 ES ES02080320T patent/ES2298327T3/es not_active Expired - Lifetime
- 2000-04-19 HU HU0200929A patent/HUP0200929A3/hu not_active IP Right Cessation
- 2000-04-19 DE DE60037602T patent/DE60037602T2/de not_active Expired - Fee Related
- 2000-04-19 PE PE2000000364A patent/PE20010040A1/es not_active Application Discontinuation
- 2000-04-19 KR KR1020017013557A patent/KR100744359B1/ko not_active IP Right Cessation
- 2000-04-19 AU AU41306/00A patent/AU765498B2/en not_active Ceased
- 2000-04-19 DK DK02080320T patent/DK1284268T3/da active
- 2000-04-19 IL IL14611000A patent/IL146110A0/xx unknown
- 2000-04-19 PL PL00351686A patent/PL351686A1/xx not_active Application Discontinuation
- 2000-04-19 AP APAP/P/2001/002333A patent/AP1495A/en active
- 2000-04-19 PT PT02080320T patent/PT1284268E/pt unknown
- 2000-04-19 EP EP00920889A patent/EP1173434B1/en not_active Expired - Lifetime
- 2000-04-19 AR ARP000101865A patent/AR023564A1/es unknown
- 2000-04-19 CN CNB008090572A patent/CN1208335C/zh not_active Expired - Fee Related
- 2000-04-19 US US10/030,323 patent/US6815457B1/en not_active Expired - Fee Related
- 2000-04-21 MY MYPI20001707A patent/MY128007A/en unknown
- 2000-04-24 UY UY26120A patent/UY26120A1/es not_active Application Discontinuation
- 2000-04-24 TW TW089107633A patent/TW591027B/zh not_active IP Right Cessation
-
2001
- 2001-10-22 MA MA26377A patent/MA26785A1/fr unknown
- 2001-10-22 HR HR20010773A patent/HRP20010773B1/xx not_active IP Right Cessation
- 2001-10-22 NO NO20015149A patent/NO320589B1/no unknown
- 2001-11-20 BG BG106119A patent/BG65427B1/bg unknown
-
2002
- 2002-06-28 HK HK02104882.1A patent/HK1045154B/zh not_active IP Right Cessation
- 2002-06-28 HK HK03105903A patent/HK1055293A1/xx not_active IP Right Cessation
-
2003
- 2003-11-07 US US10/703,887 patent/US20040092555A1/en not_active Abandoned
-
2008
- 2008-03-12 CY CY20081100277T patent/CY1107238T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20010773A2 (en) | Thiazolidinedione derivative and its use as antidiabetic | |
| HRP20010772A2 (en) | Polymorph of 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, maleic acid salt | |
| KR100549141B1 (ko) | 치환된 티아졸리딘디온 유도체, 그의 제조 방법 및 제약상용도 | |
| KR100549142B1 (ko) | 약제로서의5-[4-[2-(ｎ-메틸-ｎ-(2-피리딜)아미노)에톡시]벤질]티아졸리딘-2,4-디온 말레산 염 수화물 | |
| HRP20010774A2 (en) | Thiazolidinedione derivative and its use as antidiabetic | |
| HRP20000405A2 (en) | Hydrate of 5-/4-/2-(n-methyl-n-(2-pyridil)amino) ethoxy)benzyl/thiazolidine-2,4-dione, maleic acid salt | |
| HRP20010770A2 (en) | Thiazolidinedione derivative and its use as antidiabetic | |
| HRP20010771A2 (en) | Thiazolidinedione derivative and its use as antidiabetic | |
| KR100917953B1 (ko) | 5-[4-[2-(ｎ-메틸-ｎ-(2-피리딜)아미노)에톡시]벤질]티아졸리딘-2,4-디온의 나트륨염 | |
| ZA200108722B (en) | Thiazolidinedione derivative and its use as antidiabetic. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A1OB | Publication of a patent application | ||
| AIPI | Request for the grant of a patent on the basis of a substantive examination of a patent application | ||
| B1PR | Patent granted | ||
| ODRP | Renewal fee for the maintenance of a patent |
Payment date: 20080402 Year of fee payment: 9 |
|
| PBON | Lapse due to non-payment of renewal fee |
Effective date: 20090420 |